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 ABSTRACT 
 
Objectives: There have been significant advances in axial spondyloarthritis (axSpA), with implications 
for service delivery. We evaluated the state of axSpA rheumatology services and how people with 
axSpA perceive their care. 
Methods: An online patient survey was emailed to all members of the National Ankylosing 
Spondylitis Society and advertised widely via social media. Separately, a Web-based questionnaire 
about axSpA services was sent to rheumatologists at all 172 acute hospital trusts in the UK. 
Results: From the National Ankylosing Spondylitis Society survey, data for 1979 surveys (56% males) 
were available for analysis. The majority of respondents had longstanding disease and identified 
their diagnosis as AS, with only 44% aware of the term axSpA. Eighty-two per cent of respondents 
were currently attending a rheumatologist, with 43% on biologic agents. Satisfaction scores for 
rheumatology care were high. Respondents’ concerns included access during disease flares and 
adverse effects of analgesics. From the rheumatology survey, the concept and terminology of axSpA 
was widely accepted by respondents (88%). The majority of centres had at least one rheumatologist 
with a specialist interest in axSpA (62%), dedicated axSpA clinics (58%) or a multidisciplinary team 
for axSpA (64%). BASDAI (99%), BASFI (74%) and BASMI (65%) were routinely performed. All centres 
had access to MRI scans, but scanning protocols varied and were often sub-optimal. 
Conclusion: Although overall satisfaction with rheumatology care was high, the results indicate 
significant unmet patient needs and discrepancies in service provision. This information will inform 
the development of quality standards for axSpA in order to improve quality and deliver equitable 
care for all patients. 
 
Keywords: spondylitis, axial spondyloarthritis, survey, service quality, rheumatology departments, 
rheumatology consultants, National Ankylosing Spondylitis Society 
 
Rheumatology key messages 
 
1. People with axial SpA are generally satisfied with their rheumatology care. 
 
2. There is significant unmet need and discrepancy in service provision for axial SpA. 
 
3. There is a need to develop quality standards and indicators for axial SpA. 
 
 
 
 
 INTRODUCTION 
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral 
joints, entheses and extra-articular systems. It is part of a group of heterogeneous conditions, 
collectively termed spondyloarthritis. The term axSpA itself is a spectrum, which incorporates both 
AS (verifiable by radiographic changes on X-ray fulfilling the modified New York criteria [1]) and non-
radiographic axSpA (diagnosed using MRI and/or clinical criteria [2]). Although a significant 
proportion of axSpA patients develop spinal fusion, this is not an inevitable consequence [3, 4]. 
 
There have been significant advances in axSpA during the past decade, most notably the ability to 
establish an earlier diagnosis using MRI, which is supported by revised classification criteria [2], and 
the availability and efficacy of an increasing number of biologic agents [5]. In order for these 
advances to be translated into meaningful improvements in patient care, they need to be 
implemented into clinical practice, which inevitably lags behind scientific evidence, thereby leading 
to variations in practice. Although rheumatology services have established early RA and biologics 
clinics driven by national guidance and standards of care [6–8], advances in axSpA have been 
implemented largely in an ad hoc manner, based on local expertise and resources. Advances in our 
understanding of divergent pathophysiology, extra-articular manifestations, co-morbidities, disease-
specific outcome measurements and biologic therapies mean that optimal management of axSpA 
can no longer be delivered effectively in general rheumatology clinics and therefore requires 
dedicated specialist axSpA services. 
 
In 2011, we published data on the medical services for people with AS in the UK [9]. Key findings 
included the fact that one-third of patients were not under the care of specialist rheumatology 
services, the diagnosis was frequently delayed and that access to TNF inhibitors (TNFi) was rationed 
in some areas [9]. In view of recent advances in our understanding of this debilitating disease and 
the availability of newer therapies during the past 5 years, we wished to evaluate how axSpA is 
currently managed, understand how people with axSpA perceive their care and identify unmet 
needs in service provision and delivery. National Institute for Health and Care Excellence (NICE) have 
recently announced that they will be developing quality standards for spondyloarthritis, so there is a 
need for published information about the status of current services to help inform this process. It 
should be noted that this work was carried out before the publication of the updated NICE and BSR 
guidelines for the use of biologics in axSpA [10, 11] and the NICE spondyloarthritis clinical guideline 
[12]. 
 
 
 
 
 
 METHODS 
 
National Ankylosing Spondyloarthritis Society survey 
The National Ankylosing Spondyloarthritis Society (NASS) is one of the largest and most active 
patient organizations [13] in Europe, with >4000 members, and is the only patient organization 
solely representing people with axSpA in the UK. The 2016, the NASS State of the Nation Survey 
survey was open to all people with axSpA living in the UK. All NASS members in the UK with 
registered email addresses were sent the survey link, which was also advertised via the NASS 
website and social media. The survey was completed online, with only one reply being accepted 
from an individual IP address, and the first 2000 replies were analysed. The survey comprised 63 
questions regarding aspects of care and service delivery. The questions were chosen based on two 
strategies: topics frequently discussed and challenged by professionals involved in the management 
and service delivery, and questions modified to allow comparison with a previously published report 
[9]. The survey questions targeted aspects of care and service delivery, including basic 
demographics, diagnosis, rheumatology services, patients’ satisfaction and expectations, access to 
physiotherapy services, medications and patient information. Unless otherwise indicated, the terms 
AS and axSpA are used interchangeably when reporting the survey results. 
 
Rheumatology department survey 
E-mails were sent to a named rheumatologist at all 172 acute hospital trusts in the UK. Consultants 
with a known interest in axSpA were included preferentially. The email contained a link to a Web-
based survey comprising 47 questions regarding professional views and service delivery relating to 
axSpA. Reminders were sent to non-responders. 
 
Analysis 
Data collected in Survey Monkey were exported to Microsoft Excel. Statistical analysis was 
performed using IBM-SPSS version 22 (TX, USA). 
 
Ethical approval 
For this survey, ethics approval was not deemed necessary, according to guidance from the National 
Health Service (NHS) health research authority [14]. 
 
 
 
 
 
RESULTS 
 
     NASS survey 
Demographics 
After exclusion of 21 (1.05%) questionnaires with missing data about either age or sex, 1979 
(98.95%) surveys, including 1111 (56.1%) male and 868 (43.9%) female participants, were analysed. 
The age range of respondents was 18–80 years, with the majority (52.6%) <55 years of age. Female 
responders were significantly younger than male responders, with 15.6% <35 years and 38.3% <45 
years of age, compared with 8.5 and 22.6% of male participants, respectively. Two hundred and 
sixteen (12.1%) respondents were current smokers. Respondents’ weighted average score was 5.5 
for overall severity of AS, 4.55 for severity of pain today and 5.97 for daily fatigue on 10-point scales 
ranging from 1, not severe at all, to 10, very severe. 
 
Diagnosis 
The diagnostic nomenclature of axSpA has changed in recent years with adoption of the ASAS 
classification criteria [2]. The majority of respondents (92.5%) stated their given diagnosis as AS, with 
only 2.7% reporting axSpA, 2.2% non-radiographic axSpA and 2.8% spondyloarthritis. 
Undifferentiated spondyloarthritis was the diagnosis reported by 0.7%. A hundred and five patients 
reported more than one diagnosis. 
 
When asked about their knowledge of axSpA, 43.8% of respondents had previously heard the term 
axSpA, whereas 49.4% had not heard this term previously and 6.8% were not sure. Interestingly, 
only 7.1% of respondents were very confident about the meaning of the term axSpA, 21.2% were 
fairly confident, 35.3% were not very confident and 36.3% were not confident at all. 
 
The majority of respondents had longstanding disease; 58.5% were diagnosed ⩾10 years ago and 
40.3% ⩾20 years ago. However, one-quarter (25.6%) had been diagnosed within the past 5 years 
and 6.0% within the past year (Fig. 1). Participants diagnosed within the past 5 years were also asked 
further questions about their journey to diagnosis. Of these respondents (488), the time interval 
between symptom onset and seeking medical attention varied significantly, with 37.6% seeing a 
health-care professional within 6 months and 27.5% waiting ⩾3 years before doing this. The interval 
between seeing a health-care professional about their symptoms and obtaining a formal diagnosis 
also varied widely; one-third (30.1%) waited ⩾10 years for a formal diagnosis. Overall, there was a 
median [interquartile range (IQR)] delay of 8.50 (3.0–16.0) years reported between symptom onset 
and diagnosis. The final diagnosis was made by rheumatologists in 86.5% and by primary care 
physicians in 5.9% of cases. People with axSpA can also present to other specialities as a 
consequence of extra-articular manifestations, but respondents reported that the diagnosis was 
made by orthopaedic surgeons in only 2.0%, gastroenterologists in 0.8%, ophthalmologists in 0.8% 
and dermatologists in 0.4%. The diagnosis was made by a physiotherapist in only two (0.4%) cases 
and by an osteopath/chiropractor in one case. 
 
Fig 1: Time since the first diagnosis of axial SpA 
 
 
 
In 490 participants who responded to the question, the diagnosis was confirmed by MRI scan in 
44.9%, X-ray in 18.0% or both in 25.9%. Thirty-seven (7.6%) respondents reported not being 
diagnosed by either of these imaging modalities, whereas 18 (3.7%) were not sure of or did not 
recall their imaging history. 
 
Rheumatology services 
The vast majority of respondents (82.1%) were currently under the care of a rheumatologist. Of 
those not currently under the care of a rheumatologist, 18.0% had never been referred and 41.6% 
had been discharged from the rheumatology clinic. A variety of other reasons accounted for the 
remaining 44.8% of those not currently attending rheumatology. 
 
Of those currently under the care of a rheumatologist, the majority (93.3%) were reviewed at least 
once a year by a member of their rheumatology team; 23% three or more times a year, 43.2% twice 
a year and 26.9% only once a year (Fig. 2). As shown in the Fig. 3, the frequency of rheumatology 
clinic review decreased with increasing age. Factors associated with higher likelihood of being under 
the care of a rheumatologist were age <65 years [odds ratio (OR) = 2.05, 95% CI: 1.55, 2.72; P < 
0.001], female gender (OR = 1.43, 95% CI: 1.09, 1.88; P = 0.010) and having a diagnosis of AS for <20 
years (OR = 2.36, 95% CI: 1.78, 3.12; P < 0.001). 
 
Fig 2: Frequency of rheumatology clinic visits in patients with axial SpA 
 
 
Fig 3: Percentage of axial SpA patients under care of a rheumatologist by age group 
 
 
Patient satisfaction and expectations of rheumatology services 
Patients were asked to rate their satisfaction with their rheumatologist on a five-point scale, ranging 
from 1 (not satisfied at all) to 5 (very satisfied). The median (IQR) satisfaction score was 4 (3–5), with 
42.8% very satisfied, 29.7% scoring 4, 18.0% scoring 3, 6.2% scoring 2 and 3.4% not satisfied at all. 
 
Participants were offered a list of options they wished their rheumatologist would do differently. 
Interestingly, 32.8% of respondents did not want their rheumatologist to do anything different. The 
most commonly requested changes related to clinic visits; 18.0% wanted to be seen quickly when in 
flare, 17.0% wanted to be seen by the same rheumatologist every time and 7.1% wanted more 
frequent clinic appointments. The other desired changes related mainly to communication; 12.2% 
wanted more advice, 8.3% wanted their rheumatologist to listen actively and read their notes and 
4.8% wanted their rheumatologist to communicate better verbally with them. 
 
Disease flares are a major issue for patients with axSpA [15–17]. Patients were asked who they were 
able to contact during a flare; 43.1% were able to contact the rheumatology helpline for this, 37.3% 
could contact their rheumatologist for advice by telephone (26.6%) or email (10.7%), and 29.1% 
were able to ask for an earlier appointment. Only 2.8% of patients preferred to contact their primary 
care physicians first, and 23.1% of respondents reported that they had other routes for contacting 
health-care professionals during flare-ups. 
 
Respondents were asked to rate their satisfaction with the help and advice they receive from their 
rheumatology department during disease flare-ups on a five-point scale ranging from 0, not satisfied 
at all, to 5, very satisfied. The majority of respondents were satisfied, scoring either 4 (26%) or 5 
(26.9%). However, a significant number were unsatisfied, scoring 1 (9.2%) or 2 (10.6%). The median 
(IQR) satisfaction score was 4 (3–5), with a weighted average of 3.51. 
 
Access to physiotherapy services 
Only 46.1% of respondents had seen a physiotherapist for their AS during the past 12 months. 
However, when asked whether they would like to see a physiotherapist for their AS, only 41.9% of 
respondents said they would like to, 22.0% were not sure and 36.1% replied that they did not want 
to see a physiotherapist. The reasons for this are unclear but might reflect the long disease duration 
of many respondents, whereas calls to the NASS helpline suggest that many are unsure what help a 
physiotherapist will give them. Only 27.2% of respondents were able to self-refer to physiotherapy 
during a flare-up of their AS, with 34.8% unsure and 38.0% not able to self-refer to physiotherapy for 
this. 
 
Medication 
Participants were asked about their current medications being taken for their AS. The most 
commonly used group of medications were NSAIDs, including cyclooxygenase-2 selective agents, 
which were currently being taken by 60.7%. A significant proportion of patients were currently 
taking medication for pain: simple analgesics (31.2%), co-codamol and opioid preparations (41.1%) 
and/or neuropathic analgesics (such as gabapentin; 17.3%). Only 3.6% were currently taking steroid 
tablets, and 7.4% had received steroid injections. Current use of synthetic DMARDs (mainly MTX and 
SSZ) was reported by 15.8%. Forty-three per cent of respondents were receiving a TNFi, with 
adalimumab (20.2%) and etanercept (13.5%) the most commonly reported. Although the majority 
(80.1%) of those currently taking TNFi knew who to contact if they had any concerns or problems 
relating to their biologic, 12% were unsure and 7.9% did not know who to contact. Only 6.6% were 
not taking any medication for their AS. 
 
Participants were asked to rate their satisfaction with the efficacy of their current medications for 
their AS symptoms. The majority indicated that they were satisfied (30.9%) or very satisfied (29.2%) 
with their medications. Participants also felt that dose reduction of TNFi in stable patients was an 
important area for research. When asked how willing they would be to reduce their TNFi dose if they 
were stable and their rheumatologist suggested this strategy, two-thirds indicated that they would 
be either quite willing (33.4%) or very willing (29.4%). Of the remaining third, 14.9% would not be 
very willing and 9.9% would not be at all willing; 12.4% were unsure. 
 
Participants were also asked about their concerns relating to their medications taken for pain (Table 
1). Concerns about side-effects of painkillers were common, with 27.1% very worried and 17.8% 
worried. In addition, 22.1% were very worried and 19% were worried about the number of 
painkillers they were taking. Respondents were generally confident of which tablets they were 
taking for pain and how often to use these. 
Table 1 
Table 1. Frequency of pain-killer intake by patients with axSpA 
 Daily As needed Don’t take / 
No response 
Paracetamol 243 (12.3%) 
 
607 (30.7%) 
 
1129 (57.0%) 
Oral NSAIDs 455 (23.0%) 
 
411 (20.8%) 
 
1113 (56.2%) 
Oral Cox-2 anti-inflammatories 249 (12.6%) 
 
88 (4.4%) 
 
1642 (83.0%) 
Topical anti-inflammatory gels, creams or sprays 66 (3.3%) 
 
361 (18.2%) 
 
1552 (78.4%) 
Co-codamol or Co-dydramol 165 (8.3%) 
 
343 (17.3%) 
 
1471 (74.3%) 
Codeine or Dihydrocodeine 89 (4.5%) 
 
137 (6.9%) 
 
1753 (88.6%) 
Tramadol 135 (6.8%) 
 
123 (6.2%) 
 
1721 (87.0%) 
 
Morphine 52 (2.6%) 
 
43 (2.2%) 
 
1884 (95.2%) 
 
Oxycodone 14 (0.7%) 
 
7 (0.4%) 
 
1958 (98.9%) 
 
Nerve pain medications 290 (14.7%) 
 
72 (3.6%) 
 
1617 (81.7%) 
 
Morphine type patches 63 (3.2) 
 
20 (1.0%) 
 
1896 (95.8%) 
 
 
 
The use of non-prescription medications was common; 66% buy non-prescription medications for 
pain (Table 2). The most commonly reported over-the-counter medications for pain were 
paracetamol (43%), oral anti-inflammatories (such as ibuprofen; 24%), topical anti-inflammatory gels 
(22%), rubefacients (12%) and natural or herbal remedies (9%). 
Table 2 
 
Table 2. Medication bought without prescription to help with axSpA-related pain 
 N % 
Oral NSAIDs 402 20.3 
Topical anti-inflammatory gels, creams or sprays 358 18.1 
Rubefacient 193 9.8 
Paracetamol 705 35.6 
Aspirin 80 4.0 
Co-codamol e.g. Solpadeine 157 7.9 
Glucosamine and or Chondroitin 105 5.3 
Natural medicine (e.g. Turmeric, Willow Bark) 152 7.7 
Don’t but any medicine from supermarket 557 28.1 
Other 97 4.9 
 
 
Patient information 
The majority of respondents (76.2%) felt that they had the opportunity at their last few 
rheumatology clinic visits to discuss issues relating to their AS that are important to them; 15.7% did 
not and 8.1% were unsure. Although most participants (67.1%) had been provided with an agreed 
treatment plan for their AS, this was verbal in 55.2%, and only 11.9% had received a written care 
plan. A quarter (25.6%) of respondents had no agreed treatment plan. 
 
Overall, most participants felt that they had received all (35.8%) or most (31.0%) of the information 
they needed regarding AS from their rheumatology department. However, a quarter (23.3%) 
reported that they had received only some of the information, and 10% had not received the 
information they needed. The most common items participants felt they would like more 
information on were as follows: coping with fatigue (39%), long-term prognosis (35%), 
understanding which symptoms should be investigated further (32%), avoiding flares (29%), coping 
with pain (27%) and how to access other services such as physiotherapy and ophthalmology (20%) 
(Table 3). 
 
 
 
 
 
 
 
 Table 3 
 
Table 3: Further information requirements of people with axSpA  
(Note: Values overlap, as patient can choose more than one answer) 
 n % 
Avoiding and managing flares 572 28.9 
Coping with pain 537 27.1 
Coping with the fatigue 778 39.3 
Coping with the mobility issues 342 17.3 
Long term prognosis 687 34.7 
Understanding which symptoms should be investigated further 631 31.9 
How to access help     404 20.4 
Information on patient support 235 11.9 
No more information 251 12.7 
Other 127 6.4 
 
 
 
 
 
     Rheumatology department survey 
Demographics 
Eighty-three out of 172 invited departments participated in the survey, yielding a 48% response rate. 
The participating centres were from 47 (56.6%) district general hospitals, 28 (33.7%) teaching 
hospitals, 7 (8.4%) tertiary referral centres and 1 (1.2%) rehabilitation centre. Only one professional 
from each department completed the survey; the respondents were 73 (88.0%) consultant 
rheumatologists, 6 (7.2%) physiotherapists, 2 (2.4%) specialist nurses and 2 (2.4%) specialist 
registrars. 
 
AxSpA clinics and multidisciplinary management 
In 51 centres, (61.5%) there was at least one clinician with a special interest in axSpA, and in 48 
(57.8%) there was a dedicated axSpA clinic. In all centres, with one exception, consultant 
rheumatologists reviewed and led the management of patients with axSpA. 
 
The frequency of rheumatology clinic review varied between units; 9.6% of centres review patients 
every 3–4 months, 65.1% every 6 months, 1 (1.2%) centre every 9 months and 22.9% annually. In 
addition, 83% of centres reported that patients could self-refer during flare-ups. 
 
There was a multidisciplinary team (MDT) involved in the management of patients with axSpA in 
63.9% of centres. In those units with an axSpA MDT, this included the following members: 
consultant rheumatologist (98.1%), physiotherapist (100%), rheumatology specialist nurse (86.8%), 
occupational therapist (56.6%) and clinical psychologist (7.5%). In addition, 87% of centres reported 
having regular musculoskeletal (MSK) radiology MDT meetings. 
 
Patients with axSpA often have other extra-articular manifestations requiring input from other 
specialists. Only 20% of centres had at least one combined clinic for patients with SpA-related 
conditions; combined Rheumatology–Dermatology (13 centres), Rheumatology–Ophthalmology (3 
centres) and Rheumatology–Gastroenterology (5 centres) clinics. However, 80% provided no 
combined clinics with other medical specialities for their axSpA patients. Eighty-three percent of 
units had access to specialist orthopaedic spinal surgery for axSpA; of whom, 30% in the same trust, 
65% in a tertiary centre and 5% in other centres. 
 
Diagnosis and imaging 
Centres were asked about their opinions regarding the axSpA concept and nomenclature. Although 
88% of respondents accepted the concept of axSpA as described by ASAS [2], 7.2% did not and 4.8% 
were unsure. When diagnosing a new patient, 31.7% of rheumatology departments used the term 
AS, 56.1% axSpA and 12.2% a variety of terms. Whenever a patient fulfilled the ASAS classification 
criteria for non-radiographic axSpA [2], 72.3% of respondents would use this term, 15.7% would not 
and 12.1% were unsure. The majority of departments (81.9%) received their new patient referrals 
from primary care, 12.1% from MSK triage clinics and 6% from other hospital specialists. 
 
The early diagnosis of axSpA relies on specialist imaging modalities, with patients being able to fulfil 
criteria for axSpA by appropriate features on either X-ray or MRI [2]. In patients presenting with 
suspected axSpA, 40.3% of the respondents would order an MRI and 23.4% a plain X-ray as the first-
line imaging investigation. A third (36.4%) of respondents would request both MRI and X-ray as first-
line investigation. All sites had access to MRI, which was on site in 90.9% and off site in 9.1%. The 
waiting time for MRI scans was 1–3 months for 55.8% and <1 month in 39.0% of centres. However, 
in 2.6% of centres, the waiting time for MRI scans was >3 months. 
 
When sacroiliac joint X-rays are normal, respondents are able to order MRI in 98.7% of centres. The 
current consensus is that in suspected axSpA, an MRI of the whole spine and sacro-iliac joints should 
be performed [18, 19]. Of the responding centres, 53.3% would request a full spine MRI, 9.1% MRI of 
sacroiliac joints and only 28.6% MRI of the whole spine and sacro-iliac joints. 
 
Clinical assessment 
The management of axSpA requires regular disease-specific assessments of disease activity and 
function. BASDAI was performed routinely by 98.8%, BASFI by 74.1% and BASMI by 65.4% of centres. 
Fifteen (18.8%) centres also reported routinely assessing work status using the work productivity 
and activity impairment questionnaire [20]. Overall, 65% of rheumatology departments performed 
at least three disease-specific assessments (BASDAI, BASMI and BSAFI) routinely. 
 
Access to treatment and advice 
Anti-TNF therapy and biosimilars. Respondent centres estimated that ∼30% (IQR: 22.0–47.5%) of 
their axSpA patients were currently receiving anti-TNF therapy. Although 39.5% of departments 
(39.5%) reported restricted ability to prescribe biologic therapies for axSpA, in only 7% of these cases 
were restrictions genuine, with the majority of restrictions being related to eligibility criteria set by 
NICE and/or the BSR guidelines [10, 11]. At the time of the survey (before the introduction of s.c. 
biosimilar TNFi), 57.1% of centres were using biosimilar infliximab, and the majority of respondents 
felt quite confident (49.4%) or very confident (26.0%) about using biosimilar TNFi. 
 
Non-radiographic axSpA and biologics. Although the survey preceded the publication of the updated 
NICE guidance and BSR treatment guidelines, 79.2% of respondents reported being able to treat 
non-radiographic axSpA patients with biologics. Patients can fulfil a diagnosis of non-radiographic 
axSpA via a number of routes, with evidence for efficacy of TNFi limited to those with positive MRI 
and/or raised CRP [21–24]. The majority of centres would consider using TNFi to treat non-
radiographic axSpA in patients who were MRI positive (98.7%) or MRI negative and CRP positive 
(25%). Only one centre reported that they would treat patients even if both MRI and CRP were 
negative. 
 
Additional services and information 
Additional physical activity services offered to patients with axSpA include hydrotherapy (on site: 
57.1%; off site: 23.4%) and intensive physiotherapy treatment programmes 26%). The main advisory 
services offered to patients were patient education programmes (52%), employment advice (39%) 
and driving advice (29.9%). The majority of units also directed patients to NASS (93.5%) or other 
charity (18.2%) resources. 
 
The majority of responding centres (93.5%) had a patient advice line, aiming to respond the same 
(25%) or next (62.5%) working day. Just over half the responding centres (55.3%) reported that they 
were involved in research related to axSpA, although two-thirds (69.7%) contributed data to the BSR 
biologics registers in ankylosing spondylitis (BSRBR-AS) register [25]. 
 
 
DISCUSSION 
Our understanding of axSpA has expanded greatly in the last decade and, in parallel, we have 
witnessed significant advances in management, including the availability of biological therapies for 
both AS and axSpA. These advances have driven the development and publication of a number of 
international and national guidelines relating to disease classification and management of axSpA [2, 
11, 26]. An important aspect of health-care delivery is the measurement of quality of care, which 
should always be considered within a given health-care setting, be multidimensional and reflect all 
stakeholders. Best possible care should be driven by consensus, evidence, protocols and guidelines 
accessible to all, and this must encompass adequate measures to drive and maintain quality [27]. 
Developing quality standards requires information about the status of current services to help this 
process. 
 
We have attempted to ascertain the level of understanding of new disease nomenclature, care 
needs and services received by a large cohort of axSpA patients. It is clear that there is a lack of 
awareness and confidence with the term axSpA among patients, with a majority neither aware of 
nor confident with the term. Among rheumatologists, 88% accepted the concept of axSpA [2], 
although only 55% would use this term for a newly diagnosed patient. This indicates that there is a 
discrepancy between the terminology that rheumatologists use and communicate to their patients 
and what patients accept and understand. Furthermore, for those diagnosed within the past 5 years, 
the median delay to diagnosis remains high at 8.5 years; this long interval between symptom onset 
and diagnosis is consistent with other recent publications [28]. Although the majority were 
diagnosed by rheumatologists, a few patients report being diagnosed by physiotherapists, which is 
worrying given that in many areas people with back pain are now triaged by MSK physiotherapists 
who may not have the expertise or access to the appropriate investigations, including MRI. In 
addition, very few patients are being diagnosed by other secondary care specialties, which is of 
concern given the high prevalence of extra-articular manifestations among axSpA patients and the 
fact that many patients first present with an extra-articular manifestation [2]. These facts all indicate 
urgent and important educational needs. 
 
Specialist axSpA clinics are offered by only 57% of NHS Trusts, although this figure has improved 
from 41% in 2011 [9]. Likewise, 61% of Trusts now indicate that they have at least one 
rheumatologist with a special interest in axSpA, compared with 53% in 2011. Sixty-three per cent 
now have an MDT with responsibility for axSpA, compared with one-third in 2011. Combined clinics 
with any other relevant speciality are being offered in only 20% of centres. Although there is a close 
working relationship with MSK radiologists, only one-third are undertaking the recommended MRI 
protocol [18]. This fact has also recently been identified by Bennett et al. [19] in a survey of MSK 
radiologists. Patient-reported outcome measures are now being undertaken in >95% of centres, with 
66% performing at least three assessment tools at each visit. Overall, the satisfaction levels with 
rheumatology care remain high, and >80% of patients are now under the current care of a 
rheumatologist, which is an improvement from 68% in the 2011 survey [9] and the estimate of 35% 
reported by Dean et al. [29] in 2016 using population-level data. Patients rely on rheumatology for 
their on-going care; however, they report difficulty in accessing care and express concerns regarding 
the need to be seen promptly during flare. This is in contrast with the rheumatologists’ view of 
patients’ ability to self-refer during flare. Interestingly, when patients having a flare do access 
rheumatology, the majority are satisfied with flare management. 
 
Physiotherapy is considered to be a core treatment in axSpA [12]. Surprisingly, only 42% of patients 
had seen a physiotherapist within the past year and consistently recognize that they do not exercise 
sufficiently. Patients and rheumatologists alike report good access to biological therapies; one-fifth 
of patients were receiving TNFi in 2011, and this figure has now increased to between 30 and 40%. 
However, a considerable number of rheumatologists continue to report restricted access to therapy, 
although this may have been ameliorated by the subsequent publication of the updated NICE and 
BSR guidelines for the use of biologics in axSpA [10, 11] and the NICE clinical guidelines for SpA [12]. 
Three-quarters of rheumatologists were confident with biosimilars and >50% had already gained 
experience at the time of the survey. The majority of centres are active in axSpA-related research 
and contribute data to the BSRBR-AS [25]. In general, patients are comfortable with the concept of 
TNFi, and two-thirds would consider dose tapering; however, there are on-going concerns regarding 
long-term use of analgesia. 
 
Empowering patients and self-management are key aspects in the management of chronic disease. 
Integral to this is access to information and education about the disease and management thereof. 
Only one-third of patients considered that they had received all the information they needed, and 
key unmet needs included advice on coping with fatigue, information on prognosis, flare 
management and pain control. 
 
Personalized care planning for long-term conditions empowers individuals, promotes independence 
and helps people to be more involved in decisions about their care. Personalized care planning is 
about addressing an individual’s full range of needs [30], and development of a care plan is a key 
NASS objective [31]. However, a written plan is still an exception (12%), although some form of care 
plan had been discussed with 55% of patients, indicating an on-going educational and long-term 
disease management need. 
 
Our work has a number of limitations. This survey was carried out in the UK, so the results may not 
be generalizable to all countries. However, international treatment recommendations are broadly 
similar throughout Europe and North America, so the principles and issues are relevant and likely to 
be similar across these areas. The response rate for the unit survey was only 48%, introducing the 
risk of participation bias. Units or individuals with a specialist interest in axSpA are more likely to 
respond to an axSpA survey, so the results presented here are likely to represent some of the better-
performing units, and results might therefore be worse among non-responders. The anonymization 
process does not allow us to compare units that responded with non-responders. As highlighted 
previously, this survey was carried out before the publication of the updated NICE and BSR 
guidelines for the use of biologics in axSpA [10, 11] and the 2017 NICE spondyloarthritis guidelines 
[12], so some units may have changed their practice subsequently in response. The forthcoming 
National Health Quality Improvement Partnership clinical audit of rheumatoid and early arthritis 
(including axSpA) [8] will serve to identify areas where service improvements are required using 
criteria derived from NICE and best practice tariffs, together with patient-recorded outcome and 
experience measures. 
 
Although the NASS survey achieved the response target, there will inevitably be some participation 
bias in the first 2000 people to respond. Response rates for individual questions also varied, 
introducing the risk of reporter bias. The responses were self-reported and could not be verified, but 
as we were primarily interested in people’s perceptions of their service, we do not feel that this is a 
significant issue. A significant proportion of participants had very long disease duration, so may have 
different experiences, needs and perceptions from those with more recent disease onset. 
Furthermore, people with axSpA who are NASS members might be more likely to attend 
rheumatology services and therefore they might be better informed about new developments and 
therapies than non-members. 
 
Conclusion 
Although there have been major advances in understanding the concept of axSpA, specifically in 
relationship to diagnosis and treatment, we have identified significant unmet patient needs, 
discrepancies and gaps in service provision that will help to inform the development of quality 
standards. 
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